CRVS Corvus Pharmaceuticals, Inc.
Healthcare$12.83+1.74%ClosedMarket Cap: $1.08B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.72
P/S
0.00
EV/EBITDA
-21.53
DCF Value
$0.02
FCF Yield
-3.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.9%
ROA
-17.4%
ROIC
-19.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-14.9M | $-13.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-12.2M | $-12.3M | $— | — |
| FY null | $0.00 | -Infinity% | $-43.0M | $-15.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-10.6M | $-10.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.3M | $-8.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-9.9M | $15.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.1M | $-12.1M | $— | — |
| FY null | $0.00 | NaN% | $-27.5M | $-62.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.3M | $-40.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-5.9M | $-4.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.3M | $-5.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-5.7M | $-6.7M | $-0.14 | — |